Comparing famotidine and antacids for treating dyspepsia
Comparing Intravenous Famotidine and Oral Antacids in the Treatment of Dyspepsia in the Emergency Department
This study is testing whether an IV medication called famotidine works better than an antacid for quickly relieving stomach pain in people with dyspepsia who come to the emergency room.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Stony Brook University Academic / other |
| Locations | 1 site (Stony Brook, New York) |
| Trial ID | NCT06241183 on ClinicalTrials.gov |
What this trial studies
This study aims to compare the effectiveness of intravenous famotidine, an H2 receptor antagonist, with oral Maalox/Mylanta, an antacid, in treating dyspepsia symptoms in patients presenting to the emergency department. Approximately 80 patients will be randomized into two groups to receive either treatment, and their pain levels will be assessed using a verbal numeric pain scale at multiple time points after administration. The study seeks to determine which treatment provides faster and more significant relief from pain associated with dyspepsia.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who present to the emergency department with dyspepsia and a pain score of at least 3.
Not a fit: Patients with hypersensitivity to the study medications, severe renal insufficiency, or those who are pregnant or nursing may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into more effective treatment options for patients suffering from dyspepsia.
How similar studies have performed: Previous studies have indicated that antacids may provide quicker symptom relief compared to H2 receptor antagonists, suggesting a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Subject Age ≥ 18 years of age 2. Patient diagnosed with dyspepsia 3. Present at the ED with upper abdominal pain score of at least 3 Exclusion Criteria: 1. Hypersensitivity to an ingredient in Maalox/ Mylanta or Famotidine 2. Moderate to Severe Renal Insufficiency (precaution) 3. Kidney Failure 4. Pregnant or Nursing 5. Verbal pain score less than 3 6. Inability to tolerate oral medications 7. Bowel Obstruction 8. Proton pump inhibitor within 2 hours of study treatment
Where this trial is running
Stony Brook, New York
- Stony Brook University Hospital — Stony Brook, New York, United States (Recruiting)
Study contacts
- Study coordinator: Adam Singer, MD
- Email: adam.singer@stonybrookmedicine.edu
- Phone: 6314447857
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.